

Publications: 10/1/18 – 9/30/19

1. Spaulding AC, Chhatwal J, Adey MG, Lawrence RT, **Beckwith CG**, von Oehsen W. Funding hepatitis C treatment in correctional facilities by using a nominal pricing mechanism. *Journal of Correctional Health Care*. 2018. Published online Oct 15, 2018.
2. Brinkley Rubinstein L, Peterson M, Arnold T, Nunn AS, **Beckwith CG**, Castonguay B, Junious E, Lewis C, **Chan PA**. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. *PLoS One* 2018; Dec 7; 13 (12): e0205593.
3. Hussong A, Gottfredson N, Bauer D, Curran P, Haroon M, Chandler R, Delaney J, Altice F, **Beckwith CG**, Feaster D, Flynn P, Gordon M, Knight K, Kuo I, Ouellet L, Quan V, Seal D, Springer S. Approaches for creating comparable measures of alcoholic use symptoms: Harmonization with eight studies of criminal justice populations. *Drug and Alcohol Dependence* 2019. Jan 1; 194: 59-68.
4. Kuo I, Liu T, Patrick R, Trezza C, Bazerman L, Castonquay B, Peterson J, Kurth A, **Beckwith CG**. Use of an mHealth intervention to improve engagement in HIV community-based care among persons recently released from a correctional facility in Washington, D.C.: A pilot study. *AIDS and Behavior* 2019. Apr; 23(4): 1016-1031.
5. Barocas, JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, **Beckwith CG**, Linas BP, Walley AY. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. *Drug and Alcohol Dependence* 2019. Jul 1; 200: 59-63.
6. Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, **Beckwith CG**, Chander G, Chandler R, Christopoulos K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews C, Mauer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load. *Clinical Infectious Diseases*. 2019 April 17. [Epub ahead of print].
7. Cook L, Starr K, Boonyaratanakornkit J, Hayden R and **Caliendo AM**. Does size matter? Comparison of extraction yield for different-sized DNA fragments by 7 different routine and 4 new circulating cell-free extraction methods. *J Clin Microbiol*. 2018 Nov 27;56(12). pii: e01061-18. doi: 10.1128/JCM.01061-18.
8. Tang L, Su Y, Gu Z, **Caliendo AM**, Pounds S, Hayden R. A Comprehensive Statistical Framework for Determination of Commutability, Accuracy and Agreement in Clinical DNAemia Assays. *J Clin Microbiol*. 2019 Jan 2;57(1). pii: e00963-18. doi: 10.1128/JCM.00963-18. Print 2019 Jan.
9. Deraney RN, Troiano D, Joseph R, Sam SS, **Caliendo AM**, Tripathi A. Vortex and centrifugation free extraction of HIV-1 RNA. *Molecular Diagnosis and Therapy*. 2019 In Press.

Publications: 10/1/18 – 9/30/19

10. Medina MM, Crowley C, Montgomery MC, Tributino A, Almonte A, Sowemimo-Coker G, Nunn A, **Chan PA**. “Disclosure of HIV Serostatus and Pre-exposure Prophylaxis Use on Internet Hookup Sites Among Men Who have Sex with Men.” *AIDS Behav*. 2018 Sep 28.
11. **Chan PA**, Montgomery M, Marak T, Bertrand T, **Flanigan TP**, Fernández AJ, Alexander-Scott N, **Garland JM**, Nunn AS. “A Nearly 50% Decrease in New HIV Diagnoses in Rhode Island from 2006-2016: Implications for Policy Development and Prevention.” *RI Med J*. 2018 Oct 1;101(8):41-45.
12. Tortelli BA, Char DM, Crane JS, Powderly WG, Salter A, **Chan PA**, Patel RR. “Comfort discussing HIV pre-exposure prophylaxis with patients among physicians in an urban emergency department.” *J Acquir Immune Defic Syndr*. 2018 Nov 5.
13. Wray TB, **Chan PA**, Kahler CW, Simpanen EM, Liu T, Mayer KH. Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-Exposure Prophylaxis among Men who have Sex with Men. *J Acquir Immune Defic Syndr*. 2018 Nov 20.
14. Patel RR, Crane JS, López J, **Chan PA**, Liu AY, Tooba R, James AS. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. *PLoS One*. 2018 Dec 8;13(12):e0209484.
15. Patel RR, Nunn AS, Mayer KH, McBride T, Brownson RC, Oliver C, Perez MM, Harrison LC, Salter A, Crane JS, **Chan PA**. Successful Linkage to Pre-Exposure Prophylaxis for HIV Prevention Using a Multicomponent Implementation Strategy Among the Uninsured/Underinsured. *AIDS Patient Care STDS*. 2019 Jan 16.
16. Raifman JR, Schwartz SR, Sosnowy CD, Montgomery MC, Almonte A, Bazzi AR, Drainoni ML, Stein MD, Willie TC, Nunn AS, **Chan PA**. Pre-exposure Prophylaxis Awareness and Use Among Cisgender Women at a Sexually Transmitted Disease Clinic. *J Acquir Immune Defic Syndr*. 2019 Jan 1;80(1):36-39.
17. Raifman J, Dean LT, Montgomery MC, Almonte A, Arrington-Sanders R, Stein MD, Nunn AS, Sosnowy CD, **Chan PA**. Racial and Ethnic Disparities in HIV Pre-exposure Prophylaxis Awareness Among Men Who have Sex with Men. *AIDS Behav*. 2019 Mar 14.
18. Moitra E, van den Berg JJ, Sowemimo-Coker G, Chau S, Nunn A, **Chan PA**. Open pilot trial of a brief motivational interviewing-based HIV pre-exposure prophylaxis intervention for men who have sex with men: preliminary effects, and evidence of feasibility and acceptability. *AIDS Care*. 2019 May 25:1-5.
19. Jin H, Marshall BDL, Raifman J, Montgomery M, Maynard MA, **Chan PA**. Changes in patient visits following the implementation of insurance billing at a sexually transmitted diseases clinic in a Medicaid Expansion state. *Sex Transm Dis*. 2019 May 27.

Publications: 10/1/18 – 9/30/19

20. Wray TB, **Chan PA**, Simpanen EM. Longitudinal effects of home-based HIV self-testing on well-being and health empowerment among men who have sex with men (MSM) in the United States. *AIDS Care*. 2019 May 31:1-7.
21. Magno L, Dourado I, Suttan-Coats C, Wilhite D, da Silva LA, Oni-Orisan O, Brown J, Soares F, Kerr L, Ransome Y, **Chan PA**, Nunn AS. Knowledge and willingness to use preexposure prophylaxis among men who have sex in Northeastern Brazil. *Global Public Health*. 2019.
22. Parente DM, **Cunha CB**, **Mylonakis EM**, Timbrook, TT: Reply to Burnham, Kakol, Vazquez-Guillamet. *Clinical Infectious Diseases* 68:1251-1252, 2018.
23. Cunha BA, Baron J, **Cunha CB**: Monotherapy with High-Dose Once-Daily Tigecycline is Highly Effective Against *Acinetobacter baumannii* and other Multidrug-Resistant (MDR) Gram-Negative Bacilli (GNB). *International Journal of Antimicrobial Agents* 52:119-120, 2018.
24. Vigliani MB, **Cunha CB**: Multiple Recurrent Abscesses due to *B. gladioli* in an Adult with IL-12 Deficiency Mimicking LGV. *ID Cases* 12: 80-83, 2018.
25. **Cunha CB**: Antimicrobial Stewardship Programs (ASP): Perspectives on Problems and Potential. *Rhode Island Medical Journal* 101:18-21, 2018
26. **Cunha CB**: Antimicrobial Stewardship Program Perspective: IV-to-PO Switch Therapy. *Rhode Island Medical Journal* 101:31-34, 2018
27. **Cunha CB**: Antimicrobial Stewardship: Principles and Practice  
*Medical Clinics of North America* 102:797-803, 2018
28. **Cunha CB**: Pharmacoeconomic Aspects of Antibiotic Stewardship Programs.  
*Medical Clinics of North America* 102:937-946, 2018
29. **Cunha CB**: Antibiotic Stewardship Programs (ASP) Perspective: Oral Antibiotic Therapy of Common Infectious Diseases  
*Medical Clinics of North America* 102:947-954, 2018
30. **Cunha CB**, Cunha BA. The Gram Stain Re-Visited: Importance in Antibiotic Stewardship Programs.  
In: Khardori N: *Bench to Bedside: Diagnostic Microbiology for the Clinician*. CRC Press, Boca Raton, 2018
31. **Cunha CB**: An Overview of Antimicrobial Stewardship Programs: Imperatives, Interventions, and Innovations. *Medical Clinics of North America* 102:xxi-xxiii, 2018
32. Cunha BA, **Cunha CB**. Viral and Mycoplasmal Pneumonias.  
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2018*

Elsevier, New York, 2018

33. **Cunha CB**, Cunha BA. Babesiosis.  
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2018*  
Elsevier, New York, 2018
34. Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, **Cu-Uvin S**, Aberg JA. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV Vaccine in women living with HIV-1. (2018) *Papillomavirus Res.* Dec; 6:15-21. doi: 10.1016/j.pvr.2018.08.002. PMC: 30118852. PMCID: PMC6121154
35. Ermel a, Tonui P, Titus M, Tong Y, Wong N, Ong'echa J, Muthoka K, Kiptoo S, Moormann A, Hogan J, Mwangi A. **Cu-Uvin S**, Loehrer PJ, Orang'o, Brown D. A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. (2019) *BMC Infect Dis.* Apr 27; 19(1):352. doi: 10.1186/s12879-019-3982-7. PMID: 31029097
36. **D'Agata EMC**, Tran D, Bautista J, Shemin D, Grima D. The Clinical and Economic Benefits of Implementing Antimicrobial Stewardship Programs in Out-Patient Hemodialysis Units. *Clin J Am Soc Nephrol* 2018;13:1389-97.
37. **D'Agata EMC**, Varu A, **Geffert SF**, Araos R, Mitchell S. Situ A, Cameron C. Acquisition of multidrug-resistant organisms in the absence of antimicrobial exposure. *Clin Infect Dis* 2018;67:1437-40.
38. **D'Agata EMC**, Lindberg C, Lindberg C, Shemin D, Rosen S. The positive effects of an antimicrobial stewardship program targeting out-patient hemodialysis facilities. *Infect Control Hosp Epi* 2018;39(12):1400-1405.
39. **D'Agata EMC**, Varu A, **Geffert SF**, Araos R, Mitchell S. Situ A, Cameron C. Acquisition of multidrug-resistant organisms in the absence of antimicrobial exposure: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2019 (*in press*)
40. Qadeer F, Shemin D, **Gillani FS**, **D'Agata EMC**. The rise in gram-negative bacteria causing blood stream infections among maintenance hemodialysis patients. *Kidney Med* 2019 (*in press*)
41. Tharmalingam N, Ribeiro NQ, da Silva DL, Cruz LIB, Shen S, dos Santos JD, Ezikovich K, **D'Agata EMC**, **Mylonakis E**, **Fuchs BB**. Auranofin is an effective agent against clinical isolates of *Staphylococcus aureus*. *Future Med Chem* (*in press*).
42. Araos R, **D'Agata EMC**. The microbiome and its role in infection control. *Infect Control Hosp Epidemiol* 2019;40:585-9. (invited editorial)

43. Kyvernitakis A, Pappas O, **Farmakiotis D**, Horn ET, Benza RL, Bailey SH, Agarwal R. Bloodstream infections in continuous flow left ventricular assist device recipients: Diagnostic and clinical implications. *ASAIO J* 2018; in press. PMID: 30234503.
44. Kitmiridou D, Aung SN, **Farmakiotis D**. Disseminated mucormycosis with positive *Aspergillus* galactomannan. *Case Rep Infect Dis* 2018; 4294013. PMID: 30675405.
45. **Farmakiotis D**, Le A, Weiss Z, Ismail N, Kubiak D, Koo S. False positive bronchoalveolar lavage galactomannan: Effect of host and cut-off value. *Mycoses* 2019; 62(3): 204-13. PMID: 30387195.
46. Cooper R, Dudley J, **Farmakiotis D**. A man with headache, fever, and neck stiffness. *JAMA* 2019; 321(16): 1624-5. PMID: 30924841.
47. Rogers R, **Farmakiotis D**. Antifungal treatment. In: Schlossberg D, Cunha CB(Editors). *Clinical Infectious Disease, 3<sup>rd</sup> Edition*. Oxford University Press. In press.
48. Junco-Fernández A, Montgomery MC, Crowley C, Bertrand T, Marak TP, Maynard MA, Gummo C, **Flanigan TP, Chan PA**. Increasing Syphilis in Rhode Island: Return of an Old Foe. *R I Med J*. 2019 Feb 1;102(1):50-54.
49. Dumenco L, Monteiro K, Collins S, Stewart C, Berkowitz L, **Flanigan T, Rich J**, George P. A qualitative analysis of interprofessional students' perceptions toward patients with opioid use disorder after a patient panel experience. *Subst Abus*. 2019 Feb 27:1-7. doi: 10.1080/08897077.2018.1546262. [Epub ahead of print]. PMID: 30810496 [PubMed - as supplied by publisher].
50. Kim W, Steele AD, Zhu W, Csatory EE, Fricke N, Dekarske MM, Jayamani E, Pan W, Kwon B, Sinita IF, Rosen JL, Conery AL, **Fuchs BB**, Vlahovska PM, Ausubel FM, Gao H, Wuest WM, **Mylonakis E**. Discovery and optimization of nTZDpa as an antibiotic effective against bacterial persisters. *ACS Infect Dis*. 2018;4(11):1540-1545. PMID:30132650
51. **Fuchs BB**, Eatemadpour S, Martel-Foley JM, Stott S, Toner M, **Mylonakis E**. Rapid Isolation and Concentration of Pathogenic Fungi Using Inertial Focusing on a Chip-Based Platform. *Front Cell Infect Microbiol*. 2019;9:27. PMID:30809512
52. Tharmalingam N, Khader R, **Fuchs BB, Mylonakis E**. The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant *Staphylococcus aureus*. *Front Microbiol*. 2019 Jul 17;10:1557.
53. Kim W, Zou G, Hari TPA, Wilt IK, Zhu W, Galle N, Faizi HA, Hendricks GL, Tori K, Pan W, Huang X, Steele AD, Csatory EE, Dekarske MM, Rosen JL, Ribeiro NQ, Lee K, Port J, **Fuchs BB**, Vlahovska PM, Wuest WM, Gao H, Ausubel FM, **Mylonakis E**. A selective membrane-targeting repurposed antibiotic with activity against persistent

methicillin-resistant *Staphylococcus aureus*. Proc Natl Acad Sci U S A. 2019 Jul 29. pii: 201904700.

54. de Sá NP, de Lima CM, dos Santos JR, da Costa MC, de Barros PP, Junqueira JC, Vaz JA, de Oliveira RB, **Fuchs BB**, **Mylonakis E**, Rosa CA, Santos DA, Johann S. A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis and candidiasis in animal models Future Sci OA. (in press).
55. Liu Q, Zheng Z, Kim W, **Fuchs BB**, **Mylonakis E**. Influence of sub-inhibitory concentrations of NH125 on biofilm formation and virulence factors of *Staphylococcus aureus* Future Med Chem (in press).
56. de Sá NP, Fátima L, de Paula LJ, Cruz LIB, TS Matos, Lino CL, de Oliveira RB, de Souza-Fagundes EM, **Fuchs BB**, **Mylonakis E**, Johann S. A bis-arylidene-cyclo-alkanone demonstrates efficacy against *Candida albicans* infection in oral and systemic murine models. J Glob Antimicrob Resist. (in press).
57. Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, **Fuchs BB**, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, **Mylonakis E**. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018;556(7699):103-107. doi: 10.1038/nature26157. PMID: 29590091.
58. Bi S, Lv QZ, Wang TT, **Fuchs BB**, Hu DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, **Mylonakis E**, Wang Y. *SDH2* is involved in proper hypha formation and virulence in *Candida albicans*. Future Microbiol (in press). PMID: 30113213
59. Porrada AMG, Terra B, Bragaa TC, Magalhã TFF, Martins CVB, da Silva DL, Ferreira Gouveia LMB, de Freitas GSJ, Santos DA, Resende-Stoianof MA, **Fuchs BB**, **Mylonakis E**, de Freitas RP, de Fátima A. Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities J Adv Res. (in press).
60. Souza ACR, **Fuchs BB**, de Souza Alves V, Jayamani E, Colombo AL, **Mylonakis E**. Pathogenesis of the *Candida parapsilosis* complex in the model host *Caenorhabditis elegans*. Genes (Basel). (in press).
61. **Fuchs BB**, Chaturvedi S, Rossini RD, de Barros PP, Torres-Velez F, Vishnu, **Mylonakis E**, Chaturvedi V. *Galleria mellonella* experimental model for bat fungal pathogen *Pseudogymnoascus destructans* and human fungal pathogen *Pseudogymnoascus pannorum*. Virulence (in press).
62. **Fuchs BB**, Tharmalingam N, **Mylonakis E**. Vulnerability of long-term care facility residents to *Clostridium difficile* infection due to microbiome disruptions. Future Microbiol 2018 Oct;13:1537-1547. doi: 10.2217/fmb-2018-0157. Epub 2018 Oct 12. Review. PMID: 30311778

63. Awewura Kwara, Hongmei Yang, Sampson Antwi, Anthony Enimil, **Fizza S. Gillani**, Albert Dompok, Antoinette Orstin, Theresa Opoku, Dennis Bostumtwe, Anima Sarfo, Lubbe Wiesner, Jennifer Norman, Wael Alghamdi, Charles A. Peloquin, Michael H. Court, David J. Greenblatt; Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old; *Antimicrobial Agents and Chemotherapy* [AAC01657-18R1], accepted for publication, October 24, 2018, Published online 11/5/2018.
64. Van den Berg, J. J., Zaller, N. D., **Gillani, F. S.**, Dunsiger, S. I., Marshall, B. D. L., Kahler, C. W., & Operario, D. (in press as of November 20, 2018). Longitudinal HIV transmission risk profiles among men who have sex with men living with HIV in the SUN Study; *American Journal of Men's Health*, published online (as of Dec 14<sup>th</sup>, 2018), at <https://doi.org/10.1177/1557988318818283>
65. Tara Bouton, **Fizza Gillani**, Shaolei Lu, Jane Carter; High rates of indeterminate tuberculosis tests among hospitalized patients -can we optimize the use of gamma interferon release assays in tuberculosis; manuscript accepted for publication in the RI Medical Journal, May 1<sup>st</sup>, 2019
66. Anthony Enimil, Sampson Antwi, Hongmei Yang, Albert Dompok, Wael A. Alghamdi, **Fizza S. Gillani**, Antoinette Orstin, Dennis Bosumtwe, Theresa Opoku, Jennifer Norman, Lubbe Wiesner, Taimour Langaee, Charles A. Peloquin, Michael H. Court, David J. Greenblatt, Awewura Kwara; Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old, manuscript accepted for publication in *Antimicrobial Agents and Chemotherapy* (AAC), July 2019
67. Patel KM, **Johnson JE**, Reece R, **Mermel LA**. Babesiosis-associated splenic rupture: A case series from a hyperendemic region. *Clin Infect Dis* 2018 Dec 12. doi: 10.1093/cid/ciy1060. [Epub ahead of print].
68. **Johnson, J and Tunkel, A.** (2019) Bacterial Meningitis. In D. Schlossberg and C. Cunha (Eds.), *Clinical Infectious Disease*, Third Edition. New York, NY: Oxford University Press.
69. **Johnson, J and Mylonakis, E.** (2019). *Listeria monocytogenes*. In J. Bennett, R. Dolin and M. Blaser (Ed), *Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases*, Ninth Edition. Philadelphia, PA: Elsevier/Saunders.
70. **R Kantor**, A DeLong, L Schreier, M Reitsma, E Kemboi, M Orido, S Obonge, R Boinett, M Rono, W Emonyi, N Buziba, L Diero. Second-Line Treatment Failure, Drug Resistance and Resistance Accumulation among HIV-Infected Patients in a Large Treatment Program in Western Kenya. *AIDS* 2018;32:2485-2496. PMID 30134290.
71. H Ji, E Enns, CJ Brumme, N Parkin, M Howison, ER Lee, R Capina, E Marinier, S Avila Rios, P Sandstrom, G Van Domselaar, R Harrigan, R Paredes, **R Kantor**, M Noguera-

- Julian. Bioinformatic data processing pipelines in support of next generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus. *Journal of the International AIDS Society*. 2018;21:e25193. PMID 30350345. PMC 6198166.
72. M Howison, M Coetzer, **R Kantor**. Measurement error and variant-calling in deep Illumina sequencing of HIV. *Bioinformatics*. 2018 Nov 8 [Epub ahead of print]. PMID 30407489.
73. Y Xu, T Liu, MJ Daniels, **R Kantor**, A Mwangi, JW Hogan. Classification using ensemble learning under weighted misclassification Loss. *Statistics in Medicine* 2019;38:2002-2012. PMID 30609090.
74. Linda Jagodzinski, Mark Manak, Holly Hack, Ying Liu, Jennifer Malia, Joanna Freeman, Nittaya Phanuphak, Mark De Souza, Eugene Kroon, Donn Colby, Nitiya Chomchey, **Michelle Lally**, Nelson Michael, Jintanat Ananworanich, and Sheila Peel. Impact of early antiretroviral therapy on detection of cell-associated HIV-1 nucleic acid in blood by the Roche COBAS TaqMan Test. *J Clin Microbiology* 57(5): e01922-18, 2019. PMID30842229
75. Saberi P, Neilands TB, **Lally MA**, Hosek SG, Hightow-Weidman L, and The Adolescent Medicine Trials Network for HIV/AIDS Interventions. The Association Between Use of Online Social Networks to Find Sex Partners and Sexually Transmitted Infection Diagnosis among Young Men who Have Sex with Men and Transgender Women Living with HIV. *Journal of the International Association of Providers of AIDS Care* (in press).
76. Appneal HJ, Caffrey AR, Jiang L, Dosa D, **Mermel LA**, LaPlante KL. Antibiotic resistance rates for *Pseudomonas aeruginosa* clinical respiratory and bloodstream isolates among the Veterans Affairs healthcare system from 2009 to 2013. *Diagn Microbiol Infect Dis* 90:311–315, 2018.
77. Bhatt S, Mehta P, Chen C, Daines DA, **Mermel LA**, Chen H-L, Kong MG. Antimicrobial efficacy and safety of a novel gas plasma-activated catheter lock solution. *Antimicrob Agents Chemother* 2018;62(8). pii: e00744-18. doi: 10.1128/AAC.00744-18.
78. Chow EJ, Smit MA, **Mermel LA**. Visitor screening and staff sick leave policies in US hospitals. *Infect Control Hosp Epidemiol* 39:1006–1009, 2018.
79. **Mermel LA**, Jefferson J, Smit MA, Auld DB. Prevention of hospital-acquired respiratory viral infections: Assessment of a multimodal intervention program. *Infect Control Hosp Epidemiol* 240:362-364, 2019.
80. **Mermel LA**. Drawing blood cultures through intravascular catheters: Controversy and update. *Infect Control Hosp Epidemiol* 2019 Mar 6:1-3. doi: 10.1017/ice.2019.37. [Epub ahead of print].



81. **Mermel LA**. Ban the handshake in winter? *Infect Control Hosp Epidemiol* 2019 Apr 10;1-2. doi: 10.1017/ice.2019.58. [Epub ahead of print].
82. Baskin KM, **Mermel LA**, Saad TF, Journeycake JM, Schaefer CM, Modi BP, Vrazas JJ, Gore B, Drews BB, Doellman D, Kocoshis SA, Abu-Elmagd KM, Towbin RB, on behalf of the Venous Access: National Guideline and Registry Development (VANGUARD) Initiative and the VANGUARD Affected Persons Advisory Panel. Evidence-based strategies and recommendations for preservation of central venous access in children. *JPEN J Parenter Enteral Nutr* <https://onlinelibrary.wiley.com/doi/abs/10.1002/jpen.1591> [Epub ahead of print].
83. Vaccines for Adult Travelers; When and Why? Chapter 10. **Mileno MD**, Lau C, **Lonks JR**, **Garland JM**, **Sanchez MC**, **Nau G** and **Larkin JM**. In *Vaccinations* Elsevier St. Louis, Missouri. Copyright 2019. Gregory A. Poland and Jennifer A. Whitaker editors.
84. Connor BA, Hamer DH, Kozarsky P, Jong E, Halstead SB, Keystone J, **Mileno MD**, Dawood R, Rogers B, Bunn WB. Japanese Encephalitis Vaccine for Travelers: Risk-benefit reconsidered. *Journal of Travel Medicine*, May 2019; 1-3.
85. Kalligeros M, **Mylonakis E**. ACP Journal Club. Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial. *Ann Intern Med*. (in press).
86. Araos R, Andreatos N, Ugalde J, Mitchell S; **Mylonakis E**, **D'Agata EMC**. The fecal microbiome among nursing home residents with advanced dementia and *Clostridium difficile*. *Dig Dis Sci* 2018 (*in press*)
87. Rowan-Nash A, Korry B, **Mylonakis E**, Belenky P. Cross-domain and viral interactions in the microbiome. *Microbiol Mol Biol Rev*. Jan 9;83(1). pii: e00044-18. doi: 10.1128/MMBR.00044-18. Print 2019 Mar. Review. PMID: 30626617
88. Cruz L, Lopes L, Ribeiro F, Sá N, Lino C, Tharmalingam N, Oliveira R, **Mylonakis E**, **Fuchs BB**, Rosa C, Johann S. Anti-*Candida albicans* activity of thiazolylhydrazone derivatives in invertebrate and murine models. *J Fungi (Basel)* 2018 Dec 12;4(4). pii: E134. doi: 10.3390/jof4040134. PMID: 30545053
89. Pliakos E, Andreatos N, Tansarli G, Ziakas PD, **Mylonakis E**. The cost-effectiveness of corticosteroids for the treatment of community-acquired pneumonia. *Chest* 2019 Apr;155(4):787-794. doi: 10.1016/j.chest.2018.11.001. Epub 2018 Nov 15. PMID: 30448195
90. Junqueira JC, **Mylonakis E**. Current status and trends in alternative models to study fungal Pathogens. *J Fungi (Basel)*. 2019 Jan 26;5(1). pii: E12. doi: 10.3390/jof5010012. PMID: 30691083
91. Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, **Mylonakis E**. Association of community factors with hospital-onset *Clostridioides (Clostridium) difficile* infection: A

- population based U.S.-wide study *EClinicalMedicine* 2019 Feb 19;8:12-19. doi: 10.1016/j.eclinm.2019.02.001. eCollection 2019 Feb. PMID: 31193719
92. Shehadeh F, Zacharioudakis IM, Zervou FZ, **Mylonakis E**. Cost-effectiveness of rapid diagnostic assays that perform directly on blood samples for the diagnosis of septic shock. *Diagn Microbiol Infect Dis*. 2019 Mar 3. pii: S0732-8893(18)30384-5. doi: 10.1016/j.diagmicrobio.2019.02.018. [Epub ahead of print] PMID: 30922592
93. Tansarli GS, Andreatos N, Pliakos EE, **Mylonakis E**. Antibiotic treatment duration for bacteremia due to Enterobacteriaceae: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. (in press).
94. Rajasekar S\*, Krishna TP\*, Tharmalingam N\*, Andivelu I\*\*, **Mylonakis E\*\***. Metal-free C-H thiomethylation of quinones using iodine and DMSO and study of antibacterial activity *ChemistrySelect*. (in press).
95. Liu H, Shashank Shukla S, Vera-Gonzalez N, Tharmalingam N, **Mylonakis E**, **Fuchs BB**, Shukla A. Auranofin releasing antibacterial and antibiofilm polyurethane intravascular catheter coatings. *Front Cell Infect Microbiol*. 2019 Feb 28;9:37. doi: 10.3389/fcimb.2019.00037. eCollection 2019. PMID: 30873389
96. Zacharioudakis Y, Zervou F, **Mylonakis E**. Carriers of *Clostridioides (Clostridium) difficile*: To the center of focus for controlling the rate of infection [letter] (in press).
97. Volpi C, Shehadeh F, **Mylonakis E**. Correlation of antimicrobial prescription rate and county income in Medicare part D. *Medicine [Baltimore]* 2019 May;98(22):e15914. doi: 10.1097/MD.00000000000015914. PMID: 31145355
98. Shehadeh F, Zacharioudakis IM, Zervou FZ, **Mylonakis E**. Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department. *PLoS ONE* 2019 May 24;14(5):e0217508. doi: 10.1371/journal.pone.0217508. eCollection 2019. PMID: 31125382
99. Feng, J, Chen Z, He L, Xiao X, Chen C, Chu J, **Mylonakis E**, Xi L. Zebrafish is a suitable host model to study *Talaromyces marneffe* infection. *Mycobiology* (in press).
100. Kalligeros M, Shehadeh F, Karageorgos SA, Zacharioudakis IM, **Mylonakis E**. MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis. *Burns* 2019 Jun 12. pii: S0305-4179(18)31091-X. doi: 10.1016/j.burns.2019.05.014. [Epub ahead of print] PMID: 31202530
101. Poudel S, Shehadeh F, Zacharioudakis IM, Tansarli GS, Zervou FN, Kalligeros M, van Aalst R, Chit A, **Mylonakis E**. The effect of influenza vaccination on the mortality and risk of hospitalization in patients with heart failure: A systematic review and meta-analysis *Open Forum Infect Dis*. 2019 Apr 2;6(4):ofz159. doi: 10.1093/ofid/ofz159. eCollection 2019 Apr. PMID: 31041354

Publications: 10/1/18 – 9/30/19

102. Nguyen MH, Clancy CJ, Pasculle AW, Pappas PG, Alangaden G, Pankey GA, Schmitt BH, Altaf Rasool A, Weinstein MP, Widen R, Hernandez DR, Wolk DM, Walsh TJ, Perfect JR, Wilson MN, **Mylonakis E**. Performance of the T2Bacteria panel for diagnosing bloodstream infections. A diagnostic accuracy study. *Ann Intern Med*. 2019 May 14. doi: 10.7326/M18-2772. [Epub ahead of print] PMID: 31083728
103. Cheng A, Kim W, Escobar I, **Mylonakis E**, Wuest W. Structure-Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids. *ACS Med Chem Lett*. (in press)
104. Accepted manuscript: “A predicted *Francisella tularensis* DXD-motif glycosyltransferase blocks immune activation” **G.J. Nau**, J. Horzempa, D. O’Dee, M.J. Brown, B.C. Russo, A. Hernandez, S.T. Dillon, J. Cheng, L.P. Kane, S. Sanker, N.A. Hukriede. 2019 *Virulence*
105. Lee KM, Love JM, Cabral DJ, Belensky P, **Opal SM**, Jamieson AM. Coinfection with Influenza A Virus and *Klebsiella oxytoca*: An underrecognized impact on host tolerance to pulmonary infections. *Frontiers of Immunology*. 2018; 9(2377)1-16. Doi: 10.3389/fimmu.2018.02377
106. Chahin A, Opal JM, **Opal SM**. Whatever happened to the Swartzman phenomenon? *Innate Immunity* 2018; 24(8): 466-479. DOI:10.1177/1753425918808008
107. **Opal SM**. Urinary tract infections in the ICU. In: Intensive Care Medicine, Irwin, Cerra, Rippe (editors), Lippincott, Williams and Wilkins, Philadelphia, PA. 8th edition, 2018. Chapter 80, pp.755-764.
108. Cross AS, **Opal SM**. “Novel Targets for Drug Development.” In: Inflammation: From Molecular and Cellular Mechanisms to the Clinic. J-M Cavaillon & M. Singer editors (1<sup>st</sup> ed.) Wiley VGH Verlag GmbH. 2018. pp 1583-1607.
109. **Opal SM**. “Innate immunity and the kidney”. In: Critical Care Nephrology (3rd ed.) Ronco, Bellomo, Kellum editors. Elsevier publishers, London, UK. 2018 chapter 82 pp. 476-482.
110. McCulloh RJ, **Opal SM**. “Sepsis management: Important Role of the pathogen.” In: Handbook of Sepsis (WJ Wiersinga and C. Seymour editors). Springer Nature Publishers. Chennai India 2018, Chapter 3, pp. 174-193.
111. Lopansri BK, Miller RR, Yager TD, McHugh L, Rapisarda A, Sampson D, Brandon RB, Brandon RA, Seldon TA, **Opal SM**, Levy M, Burke JP. Physician agreement on the diagnosis of sepsis in the ICU. *Journal of Intensive Care* 2019; 7:13 doi.org/101186/s40560-019-0368-2.

112. Stober VP, Lim Y-P, **Opal SM**, Zhuo L, Kimata K, Garantziotis S. Inter alpha inhibitor ameliorates endothelial inflammation in sepsis. *Lung* 2019; <https://doi.org/10.1007/s.oo408-019-0028-1>.
113. Seymour CW, Kennedy JN, Wang S, Chang C-C H, Elliot CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, Huang D, Kellum JA, Mi Q, **Opal SM**, Talisa V, van der Poll T, Visweswaran S, Vodovotz Y, Weiss JC, Yealy DM, Yende S, Angus DC. Clinical sepsis phenotypes at presentation: derivation, validation, and significance for randomized trials. *JAMA* 2019 published on line May 19, doi:10.1001/jama.2019.5791.
114. Vincent J-L, Francois B, Zabolitskikh I, Daga MK, Lascarrou J-B, Kirov MY, Petillä V, Wittebole X, Meziani F, Mercier E, Lobo S, Crowther M, Esmon CT, Fareed F, Gando S, Gorelick KJ, Levi M, Jean-Paul Mira J-P, **Opal SM**, Parrillo J, Saito H, Tsuruta K, Sakai T, Fineberg D. Effect of ART-123, a recombinant human soluble thrombomodulin, on mortality in patients with sepsis-associated coagulopathy, *JAMA* 2019 published on line May 19, 2019. Doi:10.1001/jama.2019.5358
115. Angus D, Kjoelbe A-L, Windeloev N, Laterre PF, Francois B, Russell J, Perner A, Lewis R, Pickers P, Carlsen J, **Opal SM**, et al. A phase 2-3 clinical trial of selepressin for the treatment of septic shock: A randomized-double blind clinical trial versus norepineprine for vasopressor dependent septic shock. *JAMA* 2019 (in Press)
116. **Opal SM**, van der Poll T, File T, McGovern PC, Tzanis E, Chitra S. The integrated study report of a first in class tetracycline derivative, omadacycline in clinical trials. *Clinical Infectious Diseases* 2019. (in Press).
117. Cheng Y, Pereira M, Raukar N, Reagan JL, Queseneberry M, Goldberg L, Borgovan T, LaFrance WC Jr, Dooner M, Deregibus M, Camussi G, **Ramratnam B**, Queseneberry P. Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles. *J Cell Physiol*. 2019 Jan 15. PMID: 30644102
118. Monnig MA, Cohen R, **Ramratnam B**, McAdams M, **Tashima K**, Monti PM. HIV Infection, HCV Co-Infection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation. *Alcohol Clin Exp Res*. 2019 Mar 25. PMID:30908642
119. Bernstein MH, Magill M, Beaudoin FL, Becker SJ, **Rich JD**. Harnessing the placebo effect: a promising method for curbing the opioid crisis? *Addiction*. 2018 Nov;113(11):2144-2145. doi: 10.1111/add.14385. Epub 2018 Aug 9. No abstract available. PMID: 29989293 [PubMed - in process].
120. Carroll JJ, **Rich JD**, Green TC. The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. *J Addict Med*. 2018 Nov/Dec;12(6):459-465. doi: 10.1097/ADM.0000000000000436. PMID: 30095563 [PubMed - in process].

Publications: 10/1/18 – 9/30/19

121. Clarke JG, Martin RA, Gresko SA, **Rich JD**. The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System. *Am J Public Health*. 2018 Oct;108(10):1323-1325. doi: 10.2105/AJPH.2018.304666. No abstract available. PMID: 30207769 [PubMed - in process].
122. Stone AC, Carroll JJ, **Rich JD**, Green TC. Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months. *Drug Alcohol Depend*. 2018 Nov 1;192:94-97. doi: 10.1016/j.drugalcdep.2018.07.019. Epub 2018 Aug 25. PMID: 30243145 [PubMed - indexed for MEDLINE].
123. Krieger MS, Goedel WC, Buxton JA, Lysyshyn M, Bernstein E, Sherman SG, **Rich JD**, Hadland SE, Green TC, Marshall BDL. Use of rapid fentanyl test strips among young adults who use drugs. *Int J Drug Policy*. 2018 Nov;61:52-58. doi: 10.1016/j.drugpo.2018.09.009. Epub 2018 Oct 18. PMID: 30344005 [PubMed - in process].
124. Coffin PO, **Rich JD**. Overdose Research: 15 Years Later. *J Urban Health*. 2019 Feb;96(1):1-5. doi: 10.1007/s11524-018-00344-y. No abstract available. PMID: 30623291 [PubMed - in process].
125. Goedel WC, Green TC, Viner-Brown S, **Rich JD**, Marshall BDL. Increased overdose mortality during the first week of the month: Revisiting the "check effect" through a spatial lens. *Drug Alcohol Depend*. 2019 Apr 1;197:49-55. doi: 10.1016/j.drugalcdep.2018.12.024. Epub 2019 Feb 12. PMID: 30776571 [PubMed - in process].
126. Spaulding AC, Graham CS, Akiyama MJ, Chhatwal J, Nijhawan AE, Ninburg MH, **Rich JD**, Strick LB, Taylor LE, Trooskin SB, Westergaard RP, Sabol WJ. HCV prevalence estimates among incarcerated persons. *Hepatology*. 2019 Apr 2. doi: 10.1002/hep.30636. [Epub ahead of print]. PMID: 30938455 [PubMed - as supplied by publisher].
127. Kishore S, Hayden M, **Rich J**. Lessons from Scott County - Progress or Paralysis on Harm Reduction? *N Engl J Med*. 2019 May 23;380(21):1988-1990. doi: 10.1056/NEJMp1901276. Epub 2019 May 1. No abstract available. PMID: 31042821 [PubMed - indexed for MEDLINE].
128. Wang EA, Macmadu A, **Rich JD**. Examining the Impact of Criminal Justice Involvement on Health Through Federally Funded, National Population-Based Surveys in the United States. *Public Health Rep*. 2019 May/Jun;134(1\_suppl):22S-33S. doi: 10.1177/0033354918824324. No abstract available. PMID: 31059413 [PubMed - in process].
129. Peterson M, **Rich J**, Macmadu A, Truong AQ, Green TC, Beletsky L, Pognon K, Brinkley-Rubinstein L. One guy goes to jail, two people are ready to take his spot: Perspectives on drug-induced homicide laws among incarcerated individuals. *Int J Drug Policy*. 2019 May

- 9;70:47-53. doi: 10.1016/j.drugpo.2019.05.001. [Epub ahead of print]. PMID: 31082662 [PubMed - as supplied by publisher].
130. Krieger D, Abe C, Pottorff A, Li X, **Rich J**, Nijhawan AE. Sexually Transmitted Infections Detected During and After Incarceration Among People with HIV: Prevalence and Implications for Screening and Prevention. *Sex Transm Dis.* **2019 Jun 7.** doi: 10.1097/OLQ.0000000000001023. [Epub ahead of print]. PMID: 31181034 [PubMed - as supplied by publisher].
131. Karanovic D, Michelow IC, Hayward, A, DeRavin SS, Delmonte OM, Grigg ME, Dobbs K, Niemela JE, Stoddard J, Zlhinai Z, **Rybak N**, Hernandez N, Pittaluga S, Rosenzweig SD, Uzel G, Notarangelo LD. Disseminated and congenital toxoplasmosis in a mother and child with activated PI3-kinase delta syndrome type 2 (APDS2): Case report and a literature review of toxoplasma infections in primary immunodeficiencies. *Frontiers in Immunology* 2019; February 14;10(77) 1-9, doi:10.3389/fimmu.2019.00077, PMID 30891027.
132. Chiang S, Sheremeta Y, Padilla R, Jenkins H, Horsburgh Jr C, Petrenko V, **Rybak NR.** Pediatric multidrug-resistant tuberculosis in Kyiv City, Ukraine. *J of Epidemiology and Global Health* 2019; Mar 9(1):56-61, doi:10.2991/jegh.k.190225.002, PMID 30932391.
133. Aldridge AM, **Touzard Romo F, Flanigan TP.** Letter to the Editor: Time to Switch Herpes Simplex Virus Oral Medications From Prescription to Over-the-Counter. *Infect Dis in Clin Practice* (2018) November; 26 (6): e93 - e94.
134. Monteiro KA, Dietrich K, Borkan J, Dumenco L, **Tunkel AR**, Dollase R, George P. Contrasting incoming medical students' attitudes: dual degree vs traditional tracks. *Family Med* 2018;50:372-375.
135. **Tunkel AR.** Biology of Infectious Disease. In: The Merck Manual, 20<sup>th</sup> edition. Porter RS, Kaplan JL, Lynn RB, Reddy MT, eds. Kenilworth, NJ: Merck Sharp & Dohme Corporation. 2018:1430-1448.
136. Wing RR, Becofshy K, **Wing EJ**, McCaffrey J, Boudreau M, Evans EW, Unick J. Behavioral and cardiovascular effect of a behavioral weight loss program for people living with AIDS. *AIDS and Behavior* (Epub ahead of print) PMID31004243